Universe Pharmaceuticals (UPC) Long-Term Deferred Tax (2020 - 2023)

Universe Pharmaceuticals has disclosed Long-Term Deferred Tax across 4 years of filings, most recently posting $599078.0 for Q3 2023.

• Long-Term Deferred Tax for Q3 2023 came in at $599078.0, down 55.55% year-over-year; the trailing twelve-month figure through Sep 2023 was $599078.0 (down 55.55% YoY), and the FY2023 annual result was $599078.0, down 55.55% from the prior year.
• Long-Term Deferred Tax came in at $599078.0 for Q3 2023 at Universe Pharmaceuticals, down from $830259.0 in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $186.5 billion in Q3 2020 to a low of $599078.0 in Q3 2023.
• The 4-year median for Long-Term Deferred Tax is $927979.0 (2021), against an average of $31.1 billion.
• Across the five-year window, Long-Term Deferred Tax tumbled 100.0% in 2021 and soared 54.91% in 2022, its largest moves.
• Universe Pharmaceuticals' Long-Term Deferred Tax stood at $186.5 billion in 2020, then sank by 100.0% to $869997.0 in 2021, then jumped by 54.91% to $1.3 million in 2022, then plunged by 55.55% to $599078.0 in 2023.
• The last three Long-Term Deferred Tax figures came in at $599078.0 (Q3 2023), $830259.0 (Q1 2023), and $1.3 million (Q3 2022), per Business Quant data.